Nobel laureate Carolyn Bertozzi describes the evolving ADC landscape and the emergence of Degrader Antibody Conjugates (DACs) on BiotechTV.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates. Firefly Bio emerged from stealth yesterday with a $94M series A. Co-Founder Carolyn Bertozzi introduces the company and explains the idea behind combining the science of antibody-drug conjugates with protein degraders. Full video: https://lnkd.in/gjyUXYpx BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE